• Baked In
  • Posts
  • 🚜 LEEF Brands Powers Ahead with Volume, Integration, and New Plays

🚜 LEEF Brands Powers Ahead with Volume, Integration, and New Plays

Good morning, loyal readers —

LEEF Brands is leaning into the parts of the business it can control — and the results are showing up in the numbers that matter most for the long term.

Extraction volume jumped 50% and distillate volume rose 67% in the third quarter, while stronger performance in hydrocarbon and solventless products helped lift blended gross margins and delivered a sharp increase in nine-month gross profit. At the same time, the company is accelerating vertical integration at Salisbury Canyon, entering California’s wholesale flower market through its Headwaters partnership, and expanding its own retail distribution reach. These moves are designed to capture more value per acre, reduce reliance on third-party channels, and position LEEF for a higher-margin future as it scales toward 2027 and beyond.

Scroll down for our full analysis…

Own Your Edge. TDR subscribers that are new customers get 15% off: https://frepouch.com/discount/DALES

💸 The Tape

LEEF Brands reported third-quarter revenue of $8.1 million, down 4% from a year ago, on extraction volume that rose 50% to 5.06 million grams. Distillate volume was up 67%. Distillate pricing was down 36%. CEO Micah Anderson’s summary, “we cannot control wholesale pricing, but we can control our cost of goods,” is the honest version of a quarter where the company did almost everything right operationally and still shrank.

The pricing problem

The release includes an illustrative figure worth pausing on: at last year’s prices, Q3 revenue would have been about $9.9 million, or 19% growth. That gap, nearly $2 million in a single quarter, is the cost of California’s distillate collapse landing on the state’s largest concentrate manufacturer. The segment data makes the damage specific. Distillate gross margin fell from 49% to 20% in twelve months. Hydrocarbon and solventless margins moved the other way, to 51% and 55% from the low 30s, which is why blended gross margin actually ticked up to 38.2% despite the distillate hit. Nine-month gross margin of 40.9% compares to 25.3% a year ago, and nine-month gross profit rose 51% to $10.1 million.

So the mix is improving and the cost structure is improving. The core product is being repriced beneath the company. That’s not a LEEF problem specifically; it’s what happens when the largest cannabis market in the country has 13 to 22 million wet pounds coming off the field in October and a licensed retail base that keeps shrinking. LEEF is simply the most exposed public operator to the input side of that equation.

What the balance sheet says

Adjusted EBITDA was negative $0.2 million for the quarter against positive $0.8 million a year ago, though nine-month adjusted EBITDA is positive $1.5 million versus a $1.3 million loss. Reported net income of $0.3 million is a derivative revaluation, not operations, and the release says so. The number that deserves attention is operating cash flow: $6.4 million used through nine months, compared with $1.7 million a year earlier. LEEF funded that gap with roughly $14.2 million in preferred and common equity raised during the year, ending September with $5.9 million in cash against about $10.3 million of notes payable, $10.1 million in derivative liabilities and a $22.8 million uncertain tax position that reflects the 280E dispute common across the sector.

That’s a tight balance sheet for a company about to spend on 180 acres of cultivation, an Arvin processing facility acquisition, GACP and EU-GMP certification work and the Himalaya distribution ramp. CFO Kevin Wilson’s line, “our focus now is on converting those investments into stronger cash flow and profitability,” acknowledges the sequencing. LEEF has spent 2026 building. It needs 2027 to pay.

The strategic response

Three moves are underway, and they fit together more coherently than the headline numbers suggest.

First, vertical integration at Salisbury Canyon. LEEF cultivated 65 acres in 2025 and 100 for the fall 2026 harvest, with the full 180-acre permitted footprint targeted for 2027. More important than acreage is biomass retention: LEEF currently keeps roughly half of what it grows, with the remainder going to the farming partner. Starting with the 2027 season, farming and post-harvest move in-house and retention goes to 100%. For a company whose margin problem is input cost against a falling output price, doubling the share of its own biomass is the single largest lever available.

Second, flower. The Headwaters partnership announced Monday puts LEEF into California’s wholesale flower market for the first time, with Headwaters supplying genetics and distribution and taking LEEF concentrates in return. Management says internal modeling suggests flower “may earn substantially higher gross profit per acre than distillate,” which is plausible given where distillate pricing sits, but no figures were offered. Flower is a different discipline, and the first commercial harvest won’t tell the story until late 2027.

Third, distribution. Himalaya, acquired in April, contributed about $1.6 million in its first full quarter, with a retail footprint of roughly 180 stores at acquisition and a target of about 380. Owning the route to shelf is how LEEF captures margin that currently goes to third-party distributors, and it’s the piece that makes the flower partnership commercially viable.

The longer bet

Behind all of it is the interstate and export thesis that brought Hirsh Jain onto the board in October. LEEF has filed DEA registration applications, started GACP certification at the ranch and the lab, and begun EU-GMP preparation. The release says discussions with “major U.S. multistate operators” are ongoing. The logic is that 180 acres of low-cost California biomass and a scaled extraction platform are worth far more as a supplier to a national or international market than as a price-taker in a single oversupplied state. That’s correct. It’s also entirely dependent on regulatory events LEEF doesn’t control, and the DEA has so far registered dispensaries, not cultivators or manufacturers, under the Schedule III medical order.

The read

LEEF is executing against a plan that makes sense: own more of the biomass, add a higher-margin product, own the distribution, position for interstate. Every operational metric that management controls moved the right way this quarter. The one it doesn’t control, distillate pricing, moved far enough the wrong way to erase the gains. The company has bought itself time with equity, but $5.9 million in cash and a negative cash flow trend means 2027 has to show the vertical integration and flower economics working in the P&L, not in the modeling. If distillate pricing stabilizes, LEEF’s volume growth becomes revenue growth overnight. If it doesn’t, the question becomes how much more equity the strategy requires before the DEA or an MSO partner changes the math.

📈 Dog Walkers

$CURLF ( ▼ 1.73% ) Expands To 81 Doors In FL

Curaleaf opened its 81st Florida dispensary in Sebring on November 18, its first store in Highlands County and its 191st nationally. The address is 4226 Sebring Parkway, in a rural stretch of south-central Florida between Lakeland and Lake Okeechobee that has had limited medical access despite a sizable retiree population, which is exactly the patient base Florida’s program serves best.

Boris Jordan’s framing was simple: “Sebring is a new market for Curaleaf,” and patients there “no longer have to travel far to shop with us.” The grand opening runs November 20 and 21 with the standard Curaleaf playbook, a free eighth for the first 25 qualifying patients spending $75 each day, a stacked bundle at $150, and Reef, Dark Heart, FIND, Anthem and the Select Briq 2 vape on the shelves.

Two stores in five weeks, Wellington and now Sebring, with Curaleaf steadily moving from 79 to 81 Florida locations while the company’s public attention has been consumed by the Aurora fight it just lost to Organigram. The pattern matters. Florida has no store cap, a patient registry near 943,000 and growing, and a medical-only structure that sits inside the Schedule III perimeter. Every Florida store Curaleaf opens is a 280E-exempt store, and the operating cash flow story that Trulieve and Verano told this quarter is the same one Curaleaf is building toward by adding doors in counties the big players skipped.

Sebring isn’t a headline. It’s the kind of store that compounds.


🗞️ The News

📺 Trade To Black

Treasury Proposes Changes to Marjuana Banking Rules | TDR Cannabis in 5

  • FinCEN proposes streamlining customer due diligence: the November 16 proposal would codify relief so an existing bank customer opening a new account doesn’t trigger fresh beneficial-ownership verification. For cannabis operators juggling multiple accounts, that’s less paperwork.

  • The catch: it’s a general rule that doesn’t touch FinCEN’s 2014 marijuana guidance, so banks still have to verify state licenses, monitor activity and file suspicious activity reports on every cannabis client.

  • The GAO’s August report found compliance cost and regulatory risk still keep banks away, with roughly 1,000 institutions filing marijuana-related SARs in 2024, a number that overstates how many actively serve the industry.

  • Shadd explains why FinCEN and the DEA are working inside the existing framework rather than rewriting it, what full rescheduling would change, and why SAFE Banking remains a separate fight in Congress. Public comment runs 60 days from publication.